Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations

Molecular Diagnosis and Therapy

Volumn 16, Issue 4, 2012, Pages 251-259

  Razga, Filip ^a   Jurcek, Tomas ^a   Zackova, Daniela ^a   Dvorakova, Dana ^a,b   Toskova, Martina ^a   Jeziskova, Ivana ^a   Mayer, Jiri ^a,b   Racil, Zdenek ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Bcr abl tyrosine kinase inhibitors; Chronic myeloid leukaemia; Dasatinib; Imatinib; Leukaemia; Nilotinib; Protein tyrosine kinase inhibitors; Protein tyrosine kinase targets.

Indexed keywords

ALPHA INTERFERON; ARABINOSIDE; BCR ABL PROTEIN; BUSULFAN; DASATINIB; HYDROXYUREA; IMATINIB; MITOXANTRONE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RESISTANCE; CANCER TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; DRUG DOSE INCREASE; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84864867324     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11635340-000000000-00000     Document Type: Article

References (43)

1. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract no. 1126]. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 1126
2. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-9 (Pubitemid 46425867)
3. KantarjianHM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540-6 (Pubitemid 350159618)
4. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-29 (Pubitemid 47629897)
5. Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations. Blood 2009; 114: 4944-53
6. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009; 27: 4204-10
7. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-83 (Pubitemid 36759665)
8. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80 (Pubitemid 32743979)
9. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-5 (Pubitemid 34525335)
10. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-25 (Pubitemid 41039112)
11. Branford S. Chronic myeloid leukemia: Molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 2007; 376-83
12. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-9 (Pubitemid 46095411)
13. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767-73 (Pubitemid 44574988)
14. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French Intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061-6 (Pubitemid 43797298)
15. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter? Blood 2009; 114: 5426-35
16. Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: Straightforward but nontrivial concept. Curr Cancer Drug Targets 2011; 11: 56-71
17. Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009; 114: 2168-71
18. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Clin Invest 2007; 117: 2562-9 (Pubitemid 47494357)
19. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110: 4005-11 (Pubitemid 350248456)
20. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-51
21. Poláková KM, Polívková V, Rulcová J, et al. Constant BCR-ABL transcript level 0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission mayindicatemutation analysis. ExpHematol 2010; 38: 20-6
22. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer program. Leukemia 2003; 17: 2318-57 (Pubitemid 38072573)
23. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - A Europe Against Cancer program. Leukemia 2003; 17: 2474-86 (Pubitemid 38072587)
24. Poláková KM, Lopotová T, Klamová H, et al. High-resolution melt curve analysis: Initial screening for mutations in BCR-ABL kinase domain. Leuk Res 2008; 32: 1236-43
25. Nicolini FE, Corm S, Le Q-H, et al. The prognosis impact of BCR-ABL P-loop mutations: Worse or not worse? Leukemia 2007; 21: 193-4 (Pubitemid 46158108)
26. Cang S, Liu D. P-loop mutations and novel theraputic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008; 1: 15
27. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133 (3421): 571-3
28. Lin EH, Jiang Y, Deng Y, et al. Cancer stem cells, endothelial progenitors, and mesenchymal stem cells: 'seed and soil' theory revisited. Gastrointest Cancer Res 2008; 2: 169-74
29. Essers MA, Ordner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458: 904-8
30. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphiapositive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-25
31. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-70 (Pubitemid 40943094)
32. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-9 (Pubitemid 43801382)
33. Jorgensen HG, Allan EK, Jordanides NE, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+CML cells. Blood 2007; 109: 4016-9 (Pubitemid 46641755)
34. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data. Cancer 2003; 98: 2636-42 (Pubitemid 37509527)
35. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patientswith accelerated-phase chronicmyelogenous leukemia - Comparison with historic experience. Cancer 2005; 103: 2099-108 (Pubitemid 40605118)
36. Khorashad JS, De Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008; 26: 4806-13
37. Soverini S, Iacobucci I, Baccarani M, et al. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 2007; 92: 437-9 (Pubitemid 350144288)
38. Azam M, Seeliger MA, Gray NS, et al. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008; 15: 1109-18
39. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-12
40. Gruber FX, Ernst T, Porkka K, et al., Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia 2012; 26: 172-7
41. Quintas-Cardama AG, Gibbons DL, Kantarjian H, et al. Mutational analysis of chronic myeloid leukemia (CML) clones reveals heightened BCRABL1 genetic instability and wild-type BCR-ABL1 exhaustion in patients failing sequential imatinib and dasatinib therapy [abstract no. 1938]. Blood (ASH Annual Meeting Abstracts) 2007; 110: 1938
42. Naka K, Hoshii A, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010; 101: 1577-81
43. Azam M, Powers JT, Einhorn W, et al. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem Biol Drug Des 2010; 75: 223-7